Adaptive Biotechnologies Corporation Common Stock
$28.61
$0.06 (+0.21%)
$27.91Day Range$28.68
Key Statistics
Market Cap
$4.57B
Shares Outstanding
159.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 27, 2019
Round Lot
100
Locale
US
Trading Data
Day Open
$28.55
Day High
$28.68
Day Low
$27.91
Volume
2.99M
VWAP
$28.45
Prev Close
$28.55
Transactions
--
Acc. Volume
--
About Adaptive Biotechnologies Corporation Common Stock
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836624 employees1165 EASTLAKE AVE E, SEATTLE, WA, 98109206-659-0067IPO Jun 27, 2019US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001478320
- Composite FIGI
- BBG001J2PFF5
- Share Class FIGI
- BBG001V0GG18
- Ticker Root
- ADPT
- SIC Code
- 2836
About Adaptive Biotechnologies Corporation Common Stock (ADPT) Stock
Adaptive Biotechnologies Corporation Common Stock (ADPT) closed the 2026-09-18 session at $28.61, up 0.21% versus the previous close (+0.06). The stock opened at $28.55 and traded between $27.91 and $28.68 during that session. Session trading volume was 3.0M shares. The volume-weighted average price (VWAP) is $28.45.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Adaptive Biotechnologies Corporation Common Stock has a market capitalization of $4.57 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. ADPT is listed on the XNAS exchange. The company employs approximately 624 people. Adaptive Biotechnologies Corporation Common Stock is headquartered in SEATTLE, WA. The recorded listing date is 2019-06-27.
On this page you can find market ADPT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.